SAN DIEGO, March 15, 2012 /PRNewswire/ -- ADVENTRX
Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that
Brian M. Culley, its Chief Executive
Officer, has been selected as a 2012 Health Hero by Combined Health
Agencies of San Diego County. His
nomination was submitted by the San Diego Chapter of the Sickle
Cell Disease Association of America. The 18th Annual Health Hero
Awards, organized by Combined Health Agencies, honors local
companies and individuals for their contributions, dedication and
commitment to the health of the San
Diego community.
"Along with my ADVENTRX colleagues, I am honored to be
recognized for our efforts to increase awareness of the fight
against sickle cell disease," stated Brian
M. Culley, Chief Executive Officer of ADVENTRX. "There
is a disappointing lack of advocacy on behalf of patients suffering
with sickle cell disease, which may help explain the lack of safe
and effective drugs for this lifelong disease that affects children
typically within the first year of life. We are proud to
develop ANX-188 as a potential new treatment for sickle cell
patients and to support the mission of increasing awareness and
understanding of sickle cell disease."
About Combined Health Agencies
Established in 1970, Combined Health Agencies is a non-profit
federation of local and national health agencies that serve the
San Diego community. Collectively,
the member agencies touch 1.6 million individuals, inspire 12,000
volunteers and invest in scientific and medical research
projects.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company focused
on developing proprietary product candidates. The Company's
lead product candidate is ANX-188, a rheologic, antithrombotic and
cytoprotective agent that improves microvascular blood flow and has
potential application in treating a wide range of diseases and
conditions, such as complications arising from sickle cell
disease. We also are developing ANX-514, a novel,
detergent-free formulation of the chemotherapy drug
docetaxel. More information can be found on the Company's web
site at www.adventrx.com.
Forward Looking Statements
ADVENTRX cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements that are based on ADVENTRX's current
expectations and assumptions. Such forward-looking statements
include, but are not limited to, statements regarding the Company's
development plans for ANX-188, including the nature and timing of
future clinical studies. Among the factors that could cause or
contribute to material differences between ADVENTRX's actual
results and those indicated from the forward-looking statements are
risks and uncertainties inherent in ADVENTRX's business, including,
but are not limited to: the potential for ADVENTRX to delay,
reduce or discontinue current and/or planned development
activities, partner its product candidates at inopportune times or
pursue less expensive but higher-risk development paths if it is
unable to raise sufficient additional capital as needed; ADVENTRX's
ability to obtain additional funding on a timely basis or on
acceptable terms, or at all; the potential for delays in the
commencement or completion of its planned clinical studies
including as a result of difficulties or delays in completing
manufacturing process development activities and manufacturing
clinical trial material; the risk of suspension or termination of a
clinical study including due to lack of adequate funding; the risk
that planned clinical studies of our product candidates, including
ANX-188, are not successful and, even if they are successful, that
the FDA could determine they are not sufficient to support an NDAs
for the product candidate; the risk that the FDA does not grant
market approval of ADVENTRX's product candidates, including
ANX-188, on a timely basis, or at all; ADVENTRX's reliance on third
parties to assist in the conduct of important aspects of its
product candidates' development programs, including the manufacture
of clinical trial material, the conduct of clinical studies and
regulatory submissions related to product approval, and that such
third parties may fail to perform as expected; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
periodic filings with the Securities and Exchange Commission.
ADVENTRX's public filings with the Securities and Exchange
Commission are available at www.sec.gov.
You are cautioned not to place undue reliance on forward-looking
statements, which speak only as of the date when made. ADVENTRX
does not intend to revise or update any forward-looking statement
set forth in this press release to reflect events or circumstances
arising after the date hereof, except as may be required by
law.
SOURCE ADVENTRX Pharmaceuticals, Inc.